Volume 23, Issue 5, Pages (May 2015)

Slides:



Advertisements
Similar presentations
Volume 19, Issue 2, Pages (February 2011)
Advertisements

Genetic Manipulation of Brown Fat Via Oral Administration of an Engineered Recombinant Adeno-associated Viral Serotype Vector  Wei Huang, Travis McMurphy,
Volume 19, Issue 1, Pages (January 2011)
Volume 15, Issue 6, Pages (June 2007)
Matrix Metalloproteinase-9 Is Required for Tumor Vasculogenesis but Not for Angiogenesis: Role of Bone Marrow-Derived Myelomonocytic Cells  G-One Ahn,
Critical Roles of Lysosomal Acid Lipase in Myelopoiesis
Volume 6, Issue 1, Pages (January 1997)
Generation of transgenic mice using lentiviral vectors: a novel preclinical assessment of lentiviral vectors for gene therapy  Masahito Ikawa, Nobushige.
Single Cell-Based Vector Tracing in Patients with ADA-SCID Treated with Stem Cell Gene Therapy  Yuka Igarashi, Toru Uchiyama, Tomoko Minegishi, Sirirat.
Volume 129, Issue 6, Pages (June 2007)
Volume 22, Issue 4, Pages (April 2014)
Volume 17, Issue 11, Pages (November 2009)
Volume 20, Issue 7, Pages (July 2012)
Therapeutic levels of fetal hemoglobin in erythroid progeny of β-thalassemic CD34+ cells after lentiviral vector-mediated gene transfer by Andrew Wilber,
Volume 25, Issue 3, Pages (March 2017)
Volume 17, Issue 9, Pages (September 2009)
Allogeneic bone marrow transplant in the absence of cytoreductive conditioning rescues mice with β-thalassemia major by Yongliang Huo, Jonathan R. Lockhart,
Volume 15, Issue 1, Pages (January 2007)
Volume 12, Issue 6, Pages (December 2005)
Generation of transgenic mice using lentiviral vectors: a novel preclinical assessment of lentiviral vectors for gene therapy  Masahito Ikawa, Nobushige.
Neeltje A Kootstra, Ryusuke Matsumura, Inder M Verma  Molecular Therapy 
Volume 20, Issue 5, Pages (May 2012)
Volume 13, Issue 6, Pages (June 2006)
Volume 3, Issue 5, Pages (November 2014)
Volume 20, Issue 5, Pages (May 2012)
Volume 25, Issue 6, Pages (June 2017)
Volume 22, Issue 3, Pages (March 2014)
Enhanced sensitivity to inhibition of SHP2, STAT5, and Gab2 expression in chronic myeloid leukemia (CML)‏ by Michaela Scherr, Anuhar Chaturvedi, Karin.
Volume 12, Issue 3, Pages (September 2005)
Molecular Therapy - Methods & Clinical Development
Expression of the MOZ-TIF2 oncoprotein in mice represses senescence
Gpr171, a putative P2Y-like receptor, negatively regulates myeloid differentiation in murine hematopoietic progenitors  Lara Rossi, Roberto M. Lemoli,
Volume 20, Issue 1, Pages (January 2012)
Volume 9, Issue 4, Pages (April 2004)
Luca Biasco, Michael Rothe, Hildegard Büning, Axel Schambach 
Control of HIV Infection In Vivo Using Gene Therapy with a Secreted Entry Inhibitor  Alexander Falkenhagen, Jastaranpreet Singh, Sabah Asad, Danila Leontyev,
Transplantation of IL-2–transduced murine bone marrow is associated with dose- dependent toxicity  Thomas Kühr, Oliver Bechter, Stephan Dirnhofer, Stephan.
Volume 25, Issue 8, Pages (August 2017)
Volume 19, Issue 1, Pages (January 2011)
Volume 20, Issue 10, Pages (October 2012)
Volume 19, Issue 3, Pages (March 2011)
Matrix Metalloproteinase-9 Is Required for Tumor Vasculogenesis but Not for Angiogenesis: Role of Bone Marrow-Derived Myelomonocytic Cells  G-One Ahn,
Deletion of the Scl +19 enhancer increases the blood stem cell compartment without affecting the formation of mature blood lineages  Dominik Spensberger,
Volume 6, Issue 1, Pages (July 2002)
Effective Gene Therapy of Mice with Congenital Erythropoietic Porphyria Is Facilitated by a Survival Advantage of Corrected Erythroid Cells  Elodie Robert-Richard,
Blimp-1 Transcription Factor Is Required for the Differentiation of Effector CD8+ T Cells and Memory Responses  Axel Kallies, Annie Xin, Gabrielle T.
Volume 11, Issue 3, Pages (September 2012)
Volume 23, Issue 1, Pages (January 2015)
Volume 6, Issue 3, Pages (March 2010)
Volume 4, Issue 2, Pages (February 2009)
Volume 19, Issue 2, Pages (February 2011)
Kiran Batta, Magdalena Florkowska, Valerie Kouskoff, Georges Lacaud 
Volume 8, Issue 6, Pages (December 2003)
Volume 15, Issue 8, Pages (August 2007)
Volume 15, Issue 11, Pages (November 2007)
Volume 21, Issue 5, Pages (May 2013)
by Yue Wei, Hong Zheng, Naran Bao, Shan Jiang, Carlos E
Volume 11, Issue 6, Pages (June 2005)
Volume 18, Issue 4, Pages (April 2010)
Molecular Therapy - Nucleic Acids
Molecular Therapy - Methods & Clinical Development
Volume 15, Issue 9, Pages (September 2007)
Volume 21, Issue 1, Pages (January 2013)
Volume 3, Issue 4, Pages (April 2001)
Volume 23, Issue 4, Pages (April 2015)
Volume 19, Issue 1, Pages (January 2011)
Volume 7, Issue 3, Pages (March 2003)
A Double-Switch Vector System Positively Regulates Transgene Expression by Endogenous microRNA Expression (miR-ON Vector)  Mario Amendola, Alice Giustacchini,
Volume 15, Issue 10, Pages (October 2007)
Volume 17, Issue 2, Pages (February 2009)
Presentation transcript:

Volume 23, Issue 5, Pages 835-844 (May 2015) Lentiviral Gene Therapy Using Cellular Promoters Cures Type 1 Gaucher Disease in Mice  Maria Dahl, Alexander Doyle, Karin Olsson, Jan-Eric Månsson, André R A Marques, Mina Mirzaian, Johannes M Aerts, Mats Ehinger, Michael Rothe, Ute Modlich, Axel Schambach, Stefan Karlsson  Molecular Therapy  Volume 23, Issue 5, Pages 835-844 (May 2015) DOI: 10.1038/mt.2015.16 Copyright © 2015 American Society of Gene & Cell Therapy Terms and Conditions

Figure 1 A low percentage of normal macrophages rescues the Gaucher disease phenotype. (a) This panel demonstrates the experimental design. The recombination efficiency of the glucosidase β-acid (GBA) gene was determined by DNA polymerase chain reaction (PCR) of clonally derived individual hematopoietic colonies from GBAflox/flox and GBAnull/flox mice at 6 months of age, bulk hematopoietic cells were analyzed for levels of GCase and GluCer. (b) The relative GCase activity in bone marrow (BM), liver, and spleen was determined in WT, GBAflox/flox, and GBAnull/flox mice (n = 3 per group) and (c) substrate accumulation in the tissues (WT, n = 6; GBAflox/flox n = 6; GBAnull/flox, n = 4). (d) BM from GBAflox/flox and GBAnull/flox mice 6 months of age was harvested and colony forming unit-granulocyte macrophage (CFU-GM) assay performed. PCR targeting the excised region of GBA gene in individual colonies (minimum of 25 per group) was performed to determine recombination efficiency (n = 3 per group). *P < 0.05, **P < 0.01, Student t-test. Error bars represent mean + SEM. Molecular Therapy 2015 23, 835-844DOI: (10.1038/mt.2015.16) Copyright © 2015 American Society of Gene & Cell Therapy Terms and Conditions

Figure 2 Schematic representation of the lentiviral vector design. The figure shows the vectors where the therapeutic vectors contain the codon optimized human glucosidase β-acid (GBA) cDNA driven by the CD68, PGK, and SFFV promoters, respectively. The negative control vector lacks the GBA gene and contains a spacer sequence downstream of the PGK promoter (PGK.Control). cPPT, central polypurine tract; RSV, Rous sarcoma virus enhancer/promoter; SD and SA, splice donor and splice acceptor sites, respectively; Ψ, packaging signal. Molecular Therapy 2015 23, 835-844DOI: (10.1038/mt.2015.16) Copyright © 2015 American Society of Gene & Cell Therapy Terms and Conditions

Figure 3 Efficient early intervention of Gaucher disease by lentiviral gene transfer. (a) Experimental design of early intervention study. (b) Transduction efficiencies at 5 weeks in peripheral blood (PGK.Control, n = 6; CD68.GBA, n = 6; PGK.GBA, n = 6; SFFV.GBA, n = 5). (c) Percentages of GFP-expressing cells in whole BM at 20 weeks post-transplant (PGK.Control, n = 8; CD68.GBA, n = 8; PGK.GBA, n = 8; SFFV.GBA, n = 7). (d) Spleen mass: body mass ratio was calculated for the GD1 transplanted mice relative to WT (WT, n = 6; PGK.Control, n = 8; CD68.GBA, n = 8; PGK.GBA, n = 8; SFFV.GBA, n = 6). (e–g) The GCase activity was determined in BM (e), spleen (f), and liver (g) for the different groups (WT, n = 6; PGK.Control, n = 8; CD68.GBA, n = 8; PGK.GBA, n = 8; SFFV.GBA, n = 7). (h–j) GluCer accumulation was measured in BM (h), spleen (i), and liver (j) (WT, n = 6; PGK.Control, n = 8; CD68.GBA, n = 8; PGK.GBA, n = 8; SFFV.GBA, n = 7). *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 Mann–Whitney U-test. Error bars represent mean + SEM. Molecular Therapy 2015 23, 835-844DOI: (10.1038/mt.2015.16) Copyright © 2015 American Society of Gene & Cell Therapy Terms and Conditions

Figure 4 Diminished Gaucher cell infiltration in treated animals. Representative histologic analysis of the BM, spleens, and livers from wild-type (WT), GD1 control vector, and therapeutic vector-treated animals 20 weeks posttransplant in the early intervention study. The untreated PGK.Control samples show samples from 6-month-old GD1 mice with infiltration of GluCer- laden cells in bone marrow (BM), spleen, and liver. Periodic acid Schiff staining. Scale bars: upper panel (BM samples); 20 μm, lower panels (spleen and liver samples); 100 μm. Molecular Therapy 2015 23, 835-844DOI: (10.1038/mt.2015.16) Copyright © 2015 American Society of Gene & Cell Therapy Terms and Conditions

Figure 5 Robust correction of manifest GD1 symptoms by lentiviral gene transfer. (a) Experimental design of late intervention study. (b) Transduction efficiencies at 5 weeks in peripheral blood (PGK.Control, n = 11; CD68.GBA, n = 10; PGK.GBA, n = 6; SFFV.GBA, n = 9). (c) Percentages of GFP-expressing cells in whole BM at 20 weeks post-transplant (PGK.Control, n = 12; CD68.GBA, n = 10; PGK.GBA, n = 9; SFFV.GBA, n = 11). (d) Spleen mass: body mass ratio was calculated for the GD1 transplanted mice relative to WT (WT, n = 7; PGK.Control, n = 12; CD68.GBA, n = 10; PGK.GBA, n = 9; SFFV.GBA, n = 11). (e–g) The GCase activity was determined in BM (e), spleen (f), and liver (g) for the different groups (WT, n = 7; PGK.Control, n = 12; CD68.GBA, n = 10; PGK.GBA, n = 9; SFFV.GBA, n = 11). (h–j) GluCer accumulation was measured in BM (h), spleen (i), and liver (j) (WT, n = 7; PGK.Control, n = 12; CD68.GBA, n = 10; PGK.GBA, n = 9; SFFV.GBA, n = 11). *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 Mann–Whitney U-test. Error bars represent mean + SEM. Molecular Therapy 2015 23, 835-844DOI: (10.1038/mt.2015.16) Copyright © 2015 American Society of Gene & Cell Therapy Terms and Conditions

Figure 6 The CD68 promoter generates relatively high GFP transgene expression in myeloid cells and macrophages. The median fluorescence activity of GFP normalized to PGK.Control in BM macrophages (Mac1+ F4/80+), monocytes (Mac1+), granulocytes (Gr1+), and T-and B-cells (CD3+ CD19+) (PGK.Control, n = 12; CD68.GBA, n = 10; PGK.GBA, n = 9; SFFV.GBA, n = 11). Error bars represent mean + SEM. Molecular Therapy 2015 23, 835-844DOI: (10.1038/mt.2015.16) Copyright © 2015 American Society of Gene & Cell Therapy Terms and Conditions

Figure 7 Gene-corrected Gaucher cells exhibit a typical lentiviral insertion profile. (a) Integration analysis was performed on bone marrow (BM) from 10- to 13-month-old mice in the treatment study at 20 weeks posttransplantation. Five mice per vector group were analyzed. (b) Vector copy number was determined in BM. (c,d) The differences in the polyclonal background (<10 reads) and the amount of prominent insertions (>100 reads). Kruskal–Wallis analysis with Dunn's correction for multiple comparisons. Molecular Therapy 2015 23, 835-844DOI: (10.1038/mt.2015.16) Copyright © 2015 American Society of Gene & Cell Therapy Terms and Conditions